Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
复制标题
定量乙型肝炎核心抗体水平是接受聚乙二醇干扰素的 HBeAg 阳性慢性乙型肝炎患者治疗反应的新预测指标
DOI：
10.7150/thno.10636
复制
发表时间：
2015-01-01
期刊：
影响因子：
12.4
通讯作者：
Wang, Gui-Qiang
中科院分区：
文献类型：
--
作者：
Hou, Feng-Qin;Song, Liu-Wei;Wang, Gui-Qiang
最近的一项研究表明，定量B型肝炎核心抗体（qAnti-HBc）水平可作为预测治疗反应的新标志物。在本研究中，我们进一步研究了qAnti-HBc水平在接受PEG-IFN治疗的HBeAg阳性患者中的预测价值。共140例HBeAg阳性患者接受PEG-IFN治疗48周，随访24周。治疗后每12周采集一次血清样品。评价基线qAnti-HBc水平对治疗应答的预测值。根据基线qAnti-HBc水平将患者进一步分为2组，比较应答率。此外，病毒学和生化参数的动力学进行了分析。达到应答的患者基线qAnti-HBc水平显著较高（血清学应答[SR]，4.52 +/- 0.36 vs. 4.19 +/- 0.58，p=0.001;病毒学应答[VR]，4.53 +/- 0.35 vs. 4.22 +/- 0.57，p=0.005;综合缓解[CR]，4.50 +/- 0.36 vs. 4.22 +/- 0.58，p=0.009））。基线qAnti-HBc是唯一与SR（p=0.008）、VR（p=0.010）和CR（p=0.019）独立相关的参数。基线qAnti-HBc水平>= 30，000 IU/mL的患者在PEG-IFN治疗中有显著更高的应答率，更多的HBV DNA抑制和更好的肝炎控制。总之，qAnti-HBc水平可能是一种新的生物标志物，用于预测接受PEG-IFN治疗的HBeAg阳性患者的治疗反应。
A recent study revealed that quantitative hepatitis B core antibody (qAnti-HBc) level could serve as a novel marker for predicting treatment response. In the present study, we further investigated the predictive value of qAnti-HBc level in HBeAg-positive patients undergoing PEG-IFN therapy. A total of 140 HBeAg-positive patients who underwent PEG-IFN therapy for 48 weeks and follow-up for 24 weeks were enrolled in this study. Serum samples were taken every 12 weeks post-treatment. The predictive value of the baseline qAnti-HBc level for treatment response was evaluated. Patients were further divided into 2 groups according to the baseline qAnti-HBc level, and the response rate was compared. Additionally, the kinetics of the virological and biochemical parameters were analyzed. Patients who achieved response had a significantly higher baseline qAnti-HBc level (serological response [SR], 4.52 +/- 0.36 vs. 4.19 +/- 0.58, p=0.001; virological response [VR], 4.53 +/- 0.35 vs. 4.22 +/- 0.57, p=0.005; combined response [CR], 4.50 +/- 0.36 vs. 4.22 +/- 0.58, p=0.009)). Baseline qAnti-HBc was the only parameter that was independently correlated with SR (p=0.008), VR (p=0.010) and CR(p=0.019). Patients with baseline qAnti-HBc levels >= 30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PEG-IFN treatment. In conclusion, qAnti-HBc level may be a novel biomarker for predicting treatment response in HBeAg-positive patients receiving PEG-IFN therapy.